Study of Obesity Control by Astragalus and Notoginseng Extrats

Chung Shan Medical University

Status: Completed

Conditions: Obesity

Treatments: Dietary Supplement: Placebo; Dietary Supplement: InnoSlim

Study type: Interventional

Funder types: Other

Identifiers

NCT03654391

CS16098

Details and patient eligibility

About

The effects of the Astragalus and Notoginseng extrats on obesity control was demonstrated in a randomized double-blind, and crossover human trial.

Full description

Obesity refers to the body due to physiological or biochemical function of the change caused by excessive accumulation of body fat, resulting in weight gain. Hence, the aim of this study was to evaluate the effects of the Astragalus and Notoginseng extrats on obesity control by a randomized double-blind and crossover human trial. Subjects with simple obesity (body mass index (BMI) ≥ 27 or body fat ≥ 30%) ingested 5 extrats (n = 19) capsules or placebo (n = 19) perday for 12 weeks of a stage. Anthropometric measurements (body weight, body fat, blood pressure) and blood biochemical markers including fasting blood glucose (FBG), albumin, total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, creatinine (Cr), blood urea nitrogen (BUN), AST, ALT were examined every six weeks.

Enrollment: 38 patients

Sex: All

Ages: 20 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body mass index (BMI) ≥ 27 or body fat ≥ 30%;
• No history of serious diseases associated with heart, liver, kidney, endocrine systems or other organs;
• No drugs consumption.

Exclusion criteria

• BMI >35;
• Alcoholic;
• US-controlled diabetics;
• Stoke in past one year;
• High blood pressure;
• Mental diseases or melancholia;
• Pregency or breast-feeding a child.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

38 participants in 2 patient groups, including a placebo group

InnoSlim

Active Comparator group

Description:

Subjects ingested 2 capsules InnoSlim® (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.

Treatment:

Dietary Supplement: InnoSlim

Placebo

Placebo Comparator group

Description:

Subjects ingested 2 capsules placebo (Control group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.

Treatment:

Dietary Supplement: Placebo